About: Instituto Bioclon

An Entity of Type: agent, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.

Property Value
dbo:abstract
  • The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation. (en)
dbo:foundingYear
  • 1990-01-01 (xsd:gYear)
dbo:industry
dbo:service
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 31926273 (xsd:integer)
dbo:wikiPageLength
  • 3819 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1061345181 (xsd:integer)
dbo:wikiPageWikiLink
dbp:foundation
  • 1990 (xsd:integer)
dbp:industry
dbp:locationCity
dbp:locationCountry
dbp:name
  • Instituto Bioclon S.A. de C.V. (en)
dbp:parent
  • Silanes Laboratories (en)
dbp:services
  • Antivenom research and development (en)
dbp:type
  • Private (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation. (en)
rdfs:label
  • Instituto Bioclon (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Instituto Bioclon S.A. de C.V. (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License